Intralesional bleomycin versus sodium tetradecyl sulphate in the management of peripheral lymphangiomas in children: a prospective comparative study
Abstract
Introduction: Surgical resection in lymphangiomas is associated with high rate of complications, recurrences and total excision is not possible in every case. Therefore, sclerotherapy have emerged as alternative mode of management. It is essential to know the efficacy of the sclerosants and the merits and demerits of the agents. However, a prospective study comparing the efficacies of the sclerosing agents exclusively on lymphangioma is lacking.
Methods: A prospective, comparative clinical trial was conducted in a tertiary health care pediatric institute among lymphangioma patients. Patients were divided into two groups by randomisation; Group A: patients in whom intralesional bleomycin injection was administered, Group B: patients in whom intralesional sodium tetradecyl sulphatewas administered. Both the groups were compared with respect to clinical presentation, efficacy of the drugs and side effects/complications.
Result: Out of 36 patients included in this study, 18 patients were treated with intralesional bleomycin and 18 patients with intralesional sodium tetradecyl sulphate. Most common site of lymphangioma was neck (44.5%) followed by axilla in 27.7% of cases. Reduction in size was noted in 15 (83.3%) patients in group A, 9(50%) had excellent response, while 6(33%) had good response. Reduction in size was noted in 12 (66%) patients in group B, 5(27%) had excellent response while 7(38%) had good response.
Conclusion: Intralesional bleomycin and sodium tetradecyl sulphate are safe and effective sclerosing agents in peripheral lymphangiomas of children, but bleomycin is more effective in reducing the size of the lesions.
Downloads
References
2. Wiegand S, Eivazi B, Zimmermann AP, Sesterhenn AM, Werner JA. Sclerotherapy of lymphangiomas of the head and neck. Head Neck. 2011 Nov;33(11):1649-55. doi: 10.1002/hed.21552. Epub 2010 Aug 24. [PubMed]
3. Okada A, Kubota A, Fukuzawa M, Imura K, Kamata S.Injection of bleomycin as a primarytherapy of cystic lymphangioma. J Pediatr Surg.1992Apr;27(4):440-3. [PubMed]
4. Kennedy TL, Whitaker M, Pellitteri P, Wood WE.Cystic hygroma/lymphangioma: a rationalapproach to management. Laryngoscope.2001Nov;111(11Pt1):1929-37. [PubMed]
5. Tanaka K, Inomata Y, Utsunomiya H, Uemoto S, Asonuma K, Katayama T,etal.Sclerosing therapy with bleomycin emulsion for lymphangioma in children. PediatrSurg Int. 1990; 5: 270-3.
6. Niramis R, Watanatittan S, Rattanasuwan T. Treatment of cystic hygroma by intralesionalbleomycin injection: experience in 70 patients. Eur J Pediatr Surg. 2010 May;20(3):178-82. doi: 10.1055/s-0030-1247548. Epub 2010 Feb 22. [PubMed]
7. Rawat JD, Sinha SK, Kanojia RP, Wakhlu A, Kureel SN, Tandon RK. Non surgical management of cystic lymphangioma. Indian J Otolaryngol Head Neck Surg. 2006 Oct;58(4):355-7. doi: 10.1007/BF03049593. [PubMed]
8. Kulungowski AM, Fishman SJ. Vascular anomalies. In: Coran AG, Adzick NS, Krummel TM, Laberge J, Shamberger RC, Caldmone AA. Editors. Pediatric Surgery. 7th ed. Elsevier Saunders 2012. Pp. 1613-30.
9. Rialon KL, Fishman SJ. Vascular and lymphatic anomalies. In: Holcomb III GW, Murphy JP, Ostie DJ. Editors. Ashcraft’s Pediatric surgery. 6th ed. Elsevier Saunders 2014. Pp. 1007-27. [PubMed]
10. Umezawa H, Maeda K, Takeuchi T, Okami Y. New antibiotics, bleomycin A and B. J Antibiot (Tokyo). 1966 Sep;19(5):200-9. [PubMed]
11. Yura J, Hashimoto T, Tsuruga N, Shibata K. Bleomycin treatment for cystic hygroma in children. Nihon Geka Hokan. 1977 Sep 1;46(5):607-14. [PubMed]
12. Mulliken JB, Glowacki J.Hemangiomas and vascular malformations in infants and children: a classificationbased on endothelialcharacteristics.PlastReconstr Surg. 1982 Mar;69(3):412-22. [PubMed]
13. Mulliken JB. Cutaneous vascular anomalies. SeminVasc Surg. 1993 Dec;6(4):204-18.
14. Svendsen PA, Wikholm G, Rodriguez M, Enoksson P, Frisén L, Stromland K, Seregard S. Direct puncture and sclerotherapy with Sotradecol: Orbital lymphatic malformations. IntervNeuroradiol. 2001 Sept; 7(3): 193-9. doi: 10.1177/159101990100700303.
15. Barsky SH, Rosen S, Geer DE, Noe JM. The nature and evolution of port wine stains: a computer-assisted study. J Invest Dermatol. 1980 Mar;74(3):154-7. [PubMed]
16. Werner JA, Dünne AA, Folz BJ, Rochels R, Bien S, Ramaswamy A, Lippert BM. Current concepts in the classification, diagnosis and treatment of hemangiomas and vascular malformations of the head and neck. Eur Arch Otorhinolaryngol 2001Mar; 258(3): 141-9.
17. Saddal NS, Sharif A, Ahmad S, Mirza F, Akhtar N, Haq A, Jan Ahmed I. Intralesional bleomycin injection: A primary therapy for peripheral lymphangiomas. Pak J Med Sci 2007; 23(2): 220-2.
18. Perper M, Cervantes J, Eber AE, Hsu VM, Alharbi M, Omair IA, Alfuralh A Nouri K. Lymphangioma Circumscriptum: Treatment Modalities for this unyielding condition. J ClinInvestigatDermatol. 2017; 5(1): 2.
19. Alomari AI, Karian VE, Lord DJ, Padua HM, Burrows PE.Percutaneoussclerotherapy for lymphatic malformations: a retrospectiveanalysis of patient-evaluatedimprovement.J VascIntervRadiol.2006Oct;17(10):1639-48.
20. Gelczer RK, Charboneau JW, Hussain S, Brown DL. Complications of percutaneous ethanol ablation. J Ultrasound Med. 1998 Aug;17(8):531-3. [PubMed]
21. Giguere CM, Bauman NM, Sato Y, Burke DK, Greinwald JH, Pransky S, Kelley P, Georgeson K, Smith RJ. Treatment of lymphangiomas with OK-432(Picibanil) sclerotherapy: a prospective multi-institutional trial. Arch Otolaryngol Head Neck Surg. 2002 Oct; 128(10): 1137-44. [PubMed]
22. Mahajan JK, Bharathi V, Chowdhary SK, Samujh R, Menon P, Rao KLN. Bleomycin as intralesional sclerosant for cystic hygromas. J Indian AssocPediatr Surg. 2004; 9: 3-7.
23. Orford J, Barker A, Thonell S, King P, Murphy J. Bleomycin therapy for cystic hygroma. J Pediatr Surg. 1995 Sep;30(9):1282-7. [PubMed]
24. Baskin D, Tander B, Bankaoğlu M.Localbleomycininjection in the treatment of lymphangioma. Eur J Pediatr Surg.2005Dec;15(6):383-6. [PubMed]
25. Zhong PQ, Zhi FX, Li R, Xue JL, Shu GY.Long-termresults of intratumorousbleomycin-A5injection for head and necklymphangioma. Oral Surg Oral Med Oral Pathol Oral RadiolEndod.1998Aug;86(2):139-44. [PubMed]
26. Nirmis R, Watanatittan S, Rattanasuwan T. Treatment of cystic hygroma by intralesional bleomycin injection: experience in 70 patients. Eur J PediatrSurg 2010 May; 20(3): 178-82. doi: 10.1055/s-0030-1247548.
27. Hapani S, Chu D, Wu S. Eosinophilic pneumonia associated with bleomycin in a patient with mediastinal seminoma: a case report. Journal of Medical Case Reports. 2010 Dec; 4: 126. doi.org/10.1186/1752-1947-4-126.
28. Ikram Ud Din, Inayat-ur-Rehman, Rasool G, Khan AR, Shah e Din. Intralesional bleomycin therapy of cystic hygroma in children. J Med Sci 2008; 16(2): 87-90.
29. Dorr RT.Bleomycinpharmacology: mechanism of action and resistance, and clinical pharmacokinetics. SeminOncol.1992Apr;19(2Suppl5):3-8. [PubMed]
30. Harjai MM, Jha M. Intralesional bleomycin and sodium tetradecyl sulphate for haemangiomas and lymphangiomas. Afr J Paediatr Surg. 2012 Jan-Apr;9(1):47-51. doi: 10.4103/0189-6725.93304. [PubMed]
31. AlGhamdi KM, Mubki TF.Treatment of lymphangiomacircumscriptum with sclerotherapy: an ignoredeffectiveremedy.J CosmetDermatol.2011Jun;10(2):156-8. doi: 10.1111/j.1473-2165.2011.00558.x. [PubMed]
32. Poonyathalang A, Preechawat P, Jiarakongmun P, Pongpech S.Sclerosingtherapy for orbitallymphangioma using sodium tetradecyl sulfate. JpnJOphthalmol. 2008 Jul-Aug;52(4):298-304. doi: 10.1007/s10384-008-0547-5. Epub 2008 Sep 5. [PubMed]
33. Okazaki T, Iwatani S, Yanai T, Kobayashi H, Kato Y, Marusasa T, Lane GJ, Yamataka A. Treatment of lymphangioma in children: our experience of 128 cases. J Pediatr Surg. 2007 Feb;42(2):386-9. [PubMed]
Copyright (c) 2017 Author (s). Published by Siddharth Health Research and Social Welfare Society
This work is licensed under a Creative Commons Attribution 4.0 International License.
OAI - Open Archives Initiative
